{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:29:09Z","timestamp":1770474549216,"version":"3.49.0"},"reference-count":107,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/17512433.2022.2032657","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T21:38:00Z","timestamp":1642714680000},"page":"51-64","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["The pharmacotherapeutics of sarcoidosis"],"prefix":"10.1080","volume":"15","author":[{"given":"Patrick","family":"Mangialardi","sequence":"first","affiliation":[{"name":"University of California Davis, School of Medicine","place":["Sacramento, USA"]},{"name":"Northern California Health Care System, Department of Medicine","place":["Mather, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richart","family":"Harper","sequence":"additional","affiliation":[{"name":"University of California Davis, School of Medicine","place":["Sacramento, USA"]},{"name":"Northern California Health Care System, Department of Medicine","place":["Mather, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E","family":"Albertson","sequence":"additional","affiliation":[{"name":"University of California Davis, School of Medicine","place":["Sacramento, USA"]},{"name":"Northern California Health Care System, Department of Medicine","place":["Mather, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200209000-00013"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-021-00160-x"},{"issue":"5","key":"e_1_3_4_6_1","first-page":"581","article-title":"Microbiological transformation of steroids\u2014X: 1-dehydro analogs of cortical steroids","volume":"18","author":"Herzog HL","year":"1962","unstructured":"Herzog HL, Hughes MT, Gentles MJ, et al. Microbiological transformation of steroids\u2014X: 1-dehydro analogs of cortical steroids. ScienceDirect. 1962;18(5):581\u2013589.","journal-title":"ScienceDirect"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(24)00526-3"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1951.03670270017007"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195102082440606"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(67)90493-X"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1973.107.4.609"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8478-7"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(97)90109-8"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.238"},{"issue":"4","key":"e_1_3_4_15_1","first-page":"215","article-title":"Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease","volume":"60","author":"Selroos O","year":"1979","unstructured":"Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979;60(4):215\u2013221.","journal-title":"Scand J Respir Dis"},{"issue":"9","key":"e_1_3_4_16_1","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","author":"Zaki MH","year":"1987","unstructured":"Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 1987;87(9):496\u2013499.","journal-title":"N Y State J Med"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.2.424"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06314"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.03.012"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07071203"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1486706"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40137"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.08.010"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-4541-1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.07.004"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-69-6-1247"},{"key":"e_1_3_4_28_1","unstructured":"Clinical and research information on drug-induced liver injury. LiverTox; 2012."},{"issue":"1","key":"e_1_3_4_29_1","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman RP","year":"2000","unstructured":"Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60\u201366.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.5603\/PiAP.2014.0069"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.3120"},{"issue":"1","key":"e_1_3_4_32_1","first-page":"26","article-title":"Management of ocular sarcoidosis","volume":"29","author":"Baughman RP","year":"2012","unstructured":"Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(1):26\u201333.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1728"},{"issue":"3","key":"e_1_3_4_34_1","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang C","year":"2019","unstructured":"Fang C, Zhang Q, Wang N, et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(3):217\u2013227.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3420143"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3283642a7a"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.5.615"},{"issue":"12","key":"e_1_3_4_38_1","first-page":"29","article-title":"Methotrexate and the liver","volume":"12","author":"Tolman KG","year":"1985","unstructured":"Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol Suppl. 1985;12(Suppl 12):29\u201334.","journal-title":"J Rheumatol Suppl"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430080088011"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14511179"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1304"},{"issue":"3","key":"e_1_3_4_42_1","first-page":"161","article-title":"Adverse effects of azathioprine","volume":"3","author":"Lawson DH","year":"1984","unstructured":"Lawson DH, Lovatt GE, Gurton CS, et al. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev. 1984;3(3):161\u2013171.","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186382.81130.ba"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13863"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.032"},{"issue":"2","key":"e_1_3_4_46_1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(25)12093-4","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis","volume":"275","author":"Cherwinski HM","year":"1995","unstructured":"Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275(2):1043\u20131049.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"e_1_3_4_47_1","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman RP","year":"2004","unstructured":"Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43\u201348.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00195010"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4777"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1427727"},{"key":"e_1_3_4_51_1","unstructured":"[package insert]. Sanofi-Aventis B NJ. Leflunomide 2015; [cited 2021 Jul 20]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020905s022lbl.pdf"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(46)90242-5"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10310-X"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200204000-00005"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70285-0"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31818d094b"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79515-5"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.013"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345596"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00603-4"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00321.x"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10733"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.11.010"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70224-1"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203396005001021"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8243-x"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(51)91643-1"},{"issue":"6","key":"e_1_3_4_70_1","first-page":"640","article-title":"Sarcoidosis apparently cured by quinacrine (atabrine) hydrochloride","volume":"67","author":"Shaffer B","year":"1953","unstructured":"Shaffer B, Cahn MM, Levy EJ. Sarcoidosis apparently cured by quinacrine (atabrine) hydrochloride. AMA Arch Derm Syphilol. 1953;67(6):640\u2013641.","journal-title":"AMA Arch Derm Syphilol"},{"issue":"4","key":"e_1_3_4_71_1","first-page":"474","article-title":"Sarcoid of the eyelids, conjunctiva, and uveal tract treated with quinacrine hydrochloride (atabrine dihydrochloride)","volume":"68","author":"Klauder JV","year":"1953","unstructured":"Klauder JV. Sarcoid of the eyelids, conjunctiva, and uveal tract treated with quinacrine hydrochloride (atabrine dihydrochloride). AMA Arch Derm Syphilol. 1953;68(4):474.","journal-title":"AMA Arch Derm Syphilol"},{"issue":"8","key":"e_1_3_4_72_1","first-page":"399","article-title":"Two cases of sarcoidosis treated with mepacrine","volume":"3","author":"S\u00f6derstrom N","year":"1961","unstructured":"S\u00f6derstrom N. Two cases of sarcoidosis treated with mepacrine. J Occup Environ Med. 1961;3(8):399.","journal-title":"J Occup Environ Med"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(61)90213-3"},{"key":"e_1_3_4_74_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis","volume":"425","author":"Siltzbach LE","year":"1964","unstructured":"Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl. 1964;425:302\u2013308.","journal-title":"Acta Med Scand Suppl"},{"issue":"4","key":"e_1_3_4_75_1","first-page":"257","article-title":"A report from the research committee of the British Tuberculosis Association","volume":"48","author":"Chloroquine in the Treatment of Sarcoidosis","year":"1967","unstructured":"Chloroquine in the Treatment of Sarcoidosis. A report from the research committee of the British Tuberculosis Association. Tubercle. 1967;48(4):257\u2013272.","journal-title":"Tubercle"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680060108015"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9809024"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(68)90225-0"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0597-3_2"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(10)80012-5"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S31064"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000426"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem378"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182098e1f"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00169413"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00051907"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"issue":"3","key":"e_1_3_4_91_1","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman MD","year":"2006","unstructured":"Rossman MD, Newman LS, and Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201\u2013208.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)50471-6"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.177"},{"issue":"1","key":"e_1_3_4_94_1","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman RP","year":"2001","unstructured":"Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(1):70\u201374.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1844-0"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2011.00276.x"},{"issue":"1","key":"e_1_3_4_97_1","first-page":"46","article-title":"Efficacy results of a 52-week trial of Adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss NJ","year":"2014","unstructured":"Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of Adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46\u201354.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.005"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.10.005"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00010"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200418020-00005"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16676194"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19126"},{"key":"e_1_3_4_104_1","unstructured":"[package Insert]. Abott Laboratories NC IL. Adalimumab; 2011 [cited 2021 Jul 20]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/adalabb123102LB.htm"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1175301"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00227014"},{"issue":"2","key":"e_1_3_4_107_1","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent M","year":"2014","unstructured":"Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91\u2013107.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.29011\/IJEACR-121.000021"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S192922"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2022.2032657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:42:02Z","timestamp":1770406922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2022.2032657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,2]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/17512433.2022.2032657"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2022.2032657","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}